Does AF Ablation Work? That’s in Question After PVI-SHAM-AF

The same finding appeared in a Medscape briefing that posed the question of the procedure’s overall value. This early coverage set the baseline that rhythm control and patient‑reported quality of life may diverge. Subsequent articles expanded the picture with details from the PVI‑SHAM‑AF sham‑controlled trial. Cardiac Wire and Medical Daily reported that the study confirmed a drop in atrial‑fibrillation recurrence after ablation yet found no improvement in quality‑of‑life scores compared with the sham arm.

IDW‑Informationsdienst Wissenschaft and the University of Leipzig press release highlighted the trial’s contribution to understanding patient‑centred outcomes, while MedPage Today described the results as a “fall” in perceived efficacy. Some outlets stressed the procedural benefit, noting the reduction in arrhythmia episodes, whereas others foregrounded the lack of quality‑of‑life gain. Cardiovascular Business framed the result as a failure to outperform a sham procedure, while News‑Medical and Medical Xpress repeated that ablation “does not improve quality of life.” The differing emphases create a mixed narrative: rhythm control is confirmed, but patient‑perceived benefit remains unproven. At present the medical community views catheter ablation as effective for rhythm control but not a guaranteed route to improved daily wellbeing.

Insurers and hospitals may reconsider reimbursement policies, while device manufacturers face pressure to demonstrate patient‑centred value. Future guidance is likely to stress careful patient selection, as the trial’s findings underscore the need to balance objective rhythm outcomes with subjective quality‑of‑life measures.